Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Earnings for Jasper Therapeutics, Inc. (JSPR)
Earnings in 2023 (TTM): $-66,093,000
According to Jasper Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-66,093,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Jasper Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-66,093,000 | $-64,465,000 |
| 2022 | $-37,685,000 | $-24,174,000 |
| 2021 | $-30,637,000 | $-23,984,000 |
| 2020 | $-31,669,000 | $-31,669,000 |
| 2019 | $-4,987,000 | $-4,987,000 |